MedMira invites investment analysts to conference call

MedMira invites investment analysts to conference call 


HALIFAX, Oct. 19  /PRNewswire-FirstCall/ -- MedMira Inc. ("MedMira") (TSX
Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through
diagnostics, today announced that it will host a conference call with analysts
to discuss the company's fourth quarter financial results beginning at 11:30
p.m. Eastern Standard Time (12:30 p.m. Atlantic) on Friday, October 22, 2004.
The call was preceded by the release of the company's fourth quarter financial
results on September 24, 2004 and are available on the MedMira web site
http://www.medmira.com/

In order to listen to the conference call, please either dial 800-814-4857 for
toll-free anywhere in Canada or the USA, or 416-640-4127 in the Toronto area.

A replay of the call will be available until 23:59 ET Friday, October 29, 2004
and may be accessed by dialing 877-289-8525 for toll-free anywhere in Canada or
the USA, or 416-640-1917 in the Toronto area and entering the pass code:
21097143 followed by the number sign anytime after the call has been ended.

About MedMira

MedMira is a leading global manufacturer and marketer of in vitro rapid
diagnostic tests for the clinical laboratory market. MedMira's tests issue
reliable, rapid diagnosis in just 3 minutes for the detection of human
antibodies in human serum, plasma or whole blood for diseases such as HIV,
hepatitis B and hepatitis C. The United States Food and Drug Administration
(FDA) and the State Food and Drug Administration (SFDA), in the People's
Republic of China, have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid
HIV Tests, respectively. MedMira has the only rapid diagnostic device to
receive these two prominent government approvals. For more details visit
MedMira's website at http://www.medmira.com/.

MedMira's Reveal(TM) and MiraWell(TM) rapid HIV tests are currently used in
clinical laboratories and hospitals where professional counseling and patient
treatment are immediately available. The Reveal(TM) G2 Rapid HIV-1 Antibody
Test is the number one test used in US hospitals according to a CDC study.
MedMira markets its rapid tests worldwide in such countries as the United
States, Canada, South Africa and China. Its corporate offices and manufacturing
are located in Halifax, Nova Scotia, Canada.

This news release contains forward-looking statements, which involves risks and
uncertainties and reflect the company's current expectation regarding future
events. Actual events could materially differ from those projected herein and
depend on a number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the company quarterly
filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility
for the adequacy or accuracy of this statement. 

DATASOURCE: MedMira Inc.



CONTACT: MedMira Contact: Dr. James Smith, [phone], or e-mail:

Copyright